Outputs are designed to change an experiment, asset or development-path decision.
BOSTON-BASED SCIENTIFIC COMPUTING
Adetera turns complex scientific data into development decisions.
A specialist scientific-computing company for plate analytics, cardiac safety and small-molecule development.
The focus is practical. We help teams turn difficult signals, complex mechanistic behavior and development uncertainty into evidence they can act on with confidence.
ADVANCED SCIENCE. REAL IMPACT.
Physics-Based Modeling
Scientific Data Intelligence
In Silico R&D
Configured to the client’s data and workflow, standalone or embedded, not fixed software.
Physics-based methods and traceable assumptions support clear interpretation and defensible use.
X-PLATFORM PORTFOLIO
X-Platforms convert difficult science into business value.
Three configurable scientific platforms address high-value decisions in screening, safety and small-molecule development. Each one is designed to improve a real scientific workflow, not just produce another output.
01
PlateX
Protects screening investment by making difficult kinetic signals usable and recovering candidates otherwise lost to noise.
Built for plate readouts that are too noisy, too artifact-heavy or too custom for rigid analytical workflows.
Plate analytics and signal rescue ↘ 02CardiX
Moves safety questions earlier, reduces late-stage surprises and supports exposure and interaction decisions.
Combines electrophysiology simulation, concentration progression and trajectory analysis to expose pattern-level liability.
Cardiac liability modeling ↘ 03SolveX
Reduces trial-and-error, material use and cycle time. Includes CrystallicX for particle shape and size engineering.
Supports earlier solvent and process choices, with clearer links to the material outcome that development actually needs.
Solvent, crystallization and particles ↘PLATEX | X-PLATFORM
PlateX turns plate readouts into decision-ready evidence.
PlateX is built for teams that cannot afford to lose real biology just because the signal is difficult, the assay is custom or the readout does not fit a standard template.
Event and parameter analytics
Across plate readers, assays and kinetic formats- Event detection and classification
- Advanced physics-based parameter extraction
- Kinetics, dose-response and well / plate QC
Advanced signal rescue
For low-SNR and artifact-heavy assays- Noise characterization, baseline and drift removal
- Recovery of defensible events with confidence scoring
WHY IT MATTERS
Shorter analysis cycles • Fewer bespoke workflows • Consistent, defensible decisions • Greater value from existing assay data
PLATEX | SIGNAL RESCUE
Low-SNR can hide valuable candidates, not prove inactivity.
Weak responses are often excluded because the data cannot support a confident conclusion. Existing screening archives may therefore contain candidates missed in earlier campaigns. PlateX is designed to separate the undecidable from the truly inactive, then focus confirmation work where the value is most likely to be recovered.
A weak or noisy response can be undecidable without being biologically inactive.
Existing screening archives can be re-evaluated without repeating the full campaign.
Physics-based rescue identifies the defensible subset for confirmation, with uncertainty made explicit.
BUSINESS VALUE
Recover stranded R&D value • Reduce false negatives • Retest only the defensible subset
CARDIX | X-PLATFORM
CardiX profiles concentration-dependent cardiac liability.
CardiX helps teams move safety questions earlier. It makes exposure progression, multi-channel behavior and combination effects easier to interpret before those questions become expensive.
INPUTS
Measured or computationally predicted ion-channel concentration-response profiles.
ARRHYTHMIA-RELEVANT LIABILITY
Single- and multi-channel simulation identifies action-potential and repolarization-instability signatures.
CONCENTRATION PROGRESSION
Exposure sweeps show how cardiac electrophysiology liability evolves with concentration.
DRUG-COMBINATION LIABILITY
Combined ion-channel profiles reveal pharmacodynamic liabilities not visible from either compound alone.
UNIQUE PHASE-SPACE
ATTRACTOR APPROACH
Adetera-specific trajectory analysis identifies pattern-level deviations beyond conventional point metrics. That helps teams see differences that are easy to miss when they only compare isolated values.
BUSINESS VALUE
Earlier risk differentiation • Concentration and combination scenarios • Better-targeted preclinical follow-up
SOLVEX | X-PLATFORM
SolveX selects the solvent, crystallization path and particle design.
Computational screening and experimental-data integration focus development on the conditions most likely to meet the process objective. The goal is to reduce avoidable iteration and improve the quality of early choices.
Rapid solvent and mixture ranking
Prioritizes solvents and blends for likely solubility and process suitability. This helps narrow the experimental field earlier.
Reaction and dissolution selection
Focuses experiments on conditions most likely to meet the process objective, with a clearer connection between screen results and next steps.
Crystallization pathway
Guides selection among cooling, antisolvent and solvent-removal routes, while keeping the target material attributes in view.
CrystallicX particle engineering
Supports crystal-habit and particle-size-distribution targeting from early screening data, so particle outcomes can be considered sooner.
BUSINESS VALUE
Fewer experiments • Lower material and expert-time burden • Earlier process choices • Better particle-attribute control
SCIENTIFIC APPROACH
Decision-first. Adjustable. Explainable.
The starting point is the development decision, not a fixed software product. Methods are selected and configured around the data, workflow and scientific question. That is what makes the platforms flexible without making them generic.
Define the decision
Clarify what experiment, asset or development-path decision the output must change. This keeps the work anchored to practical value.
Represent the science
Use mechanistic relationships, physical constraints and traceable assumptions so the method remains understandable and scientifically defensible.
Configure the platform
Adapt the analytical workflow to the client’s data and operating environment. The objective is fit for purpose, not template compliance.
Deliver usable evidence
Make confidence, uncertainty and next-step implications explicit, so teams can act without losing sight of what the evidence can and cannot support.
PHYSICS-BASED MODELING
IN VITRO DATA INTELLIGENCE
IN SILICO R&D
SCIENTIFIC DECISION SUPPORT
ABOUT ADETERA
Scientific computing for pharmaceutical development.
Adetera is a Boston-based specialist scientific-computing company focused on plate analytics, cardiac safety and small-molecule development.
Adetera combines physics-based modeling, scientific data intelligence and in silico R&D to turn difficult experimental and simulated data into defensible development decisions. X-Platforms can be delivered as focused analyses, adjustable workflows or embedded scientific capabilities.
The company is built around the idea that better scientific decisions do not come from generic dashboards or black-box outputs. They come from methods that respect the underlying science, fit the workflow and make uncertainty visible instead of hiding it.
BOSTON, MASSACHUSETTS
Bring us the difficult scientific question.
For X-Platform discussions, pilot opportunities and scientific collaborations. If your data are complex, noisy or hard to interpret, that is usually the right starting point for a conversation.
contact@adetera.com↗